Japanese pharmaceutical giant Takeda recently announced its coronavirus (COVID-19) therapy. The anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) is in development to treat infected, high-risk individuals with COVID-19. The industry sponsor is also exploring the...